Caffeic Acid Phenethyl Ester

Caffeic Acid Phenethyl Ester

SCHEMBL490546

O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B10 O60218 5/20 1.00
AKR1B1 P15121 5/20 1.00
TTR P02766 5/20 1.00
APP P05067 5/20 1.00
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 2/20 1.00
ALOX12 P18054 2/20 1.00
MAPK1 P28482 2/20 1.00
HSD17B10 Q99714 2/20 1.00
ALOX5 P09917 2/20 1.00
KDM4E B2RXH2 1/20 1.00
MEN1 O00255 1/20 1.00
GMNN O75496 1/20 1.00
ALDH1A1 P00352 1/20 1.00
EGFR P00533 1/20 1.00
LMNA P02545 1/20 1.00
ESR1 P03372 1/20 1.00
ERBB2 P04626 1/20 1.00
LCK P06239 1/20 1.00
FYN P06241 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Caffeic Acid Phenethyl Ester SCHEMBL28294426 1.00 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL93649 1.00 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL30070826 1.00 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL30695557 0.99 TTR (0.97) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL38666014 0.96 TTR (0.93) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL15378852 0.95 APP (0.90) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL2602741 0.92 APP (0.85) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL20604716 0.91 APP (0.83) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL19359013 0.90 APP (0.81) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL20604718 0.90 APP (0.81) AKR1B10AKR1B1TTRAPPCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137644-A1 COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER XMK THERAPEUTICS INC. (CA) 2026-05-21 US claimed
WO-2026087695-A1 TREATMENT FOR METABOLIC DISORDER SAPREME TECHNOLOGIES B.V. (NL) 2026-04-30 WO claimed
WO-2026087680-A1 TREATMENT FOR CARDIOVASCULAR DISEASE SAPREME TECHNOLOGIES B.V. (NL) 2026-04-30 WO claimed
US-20260091016-A1 Composition for preventing and/or combating neuroinflammation, particularly in neuropsychiatric and neurological diseases BEE TERAPI (FR) 2026-04-02 US claimed
EP-4701427-A1 THERMAL ENERGY SYSTEM FOR ADMINISTERING ACTIVE AGENTS UltraOral Ltd. (IL) 2026-03-04 EP claimed
WO-2025234960-A1 BONE TISSUE TREATMENT APPARATUS UMGE DİŞ MALZEMELERİ VE EKİPMANLARI PAZARLAMA SANAYİ TİCARET LİMİTED ŞİRKETİ (TR) 2025-11-13 WO claimed
EP-4598508-A1 POLYPHENOLIC SUBSTANCE FORMULATION WITH ANTI-CANCEROGENIC EFFECT Istanbul Universitesi Rektorlugu (TR) 2025-08-13 EP claimed
CN-119219881-B Polymer material for preparing tray product, and preparation method and application thereof 山东一诺威新材料有限公司 2025-05-02 CN claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
CN-119219881-A Polymer material for preparing tray product, and preparation method and application thereof 山东一诺威新材料有限公司 2024-12-31 CN claimed
CN-108181388-A A kind of method for differentiating willow type propolis and yang gum 中国农业科学院蜜蜂研究所 2018-06-19 CN claimed
US-20180117067-A1 METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS BAYLOR RESEARCH INSTITUTE 2018-05-03 US claimed
CN-107157978-A Treat EBV+DLBCL and DLBCL medicine and composition 中国药科大学 2017-09-15 CN claimed
CN-106924251-A A kind of pharmaceutical composition and its application for treating glioma 中国药科大学 2017-07-07 CN claimed
WO-2016160880-A1 METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS BAYLOR RESEARCH INSTITUTE (US) 2016-10-06 WO claimed
US-20150274633-A2 PAIN RELIEF COMPOUNDS UNIVERSITÉ CLERMONT AUVERGNE (FR) 2015-10-01 US claimed
US-20150038466-A1 PAIN RELIEF COMPOUNDS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) 2015-02-05 US claimed
CN-101774918-A Preparation method of cinnamate derivates UNIV HUAQIAO 2010-07-14 CN claimed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US claimed
CN-101203278-A Ultraviolet protection MERCK PATENT GMBH (DE) 2008-06-18 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 AKR1B10 1257/4885AKR1B1 1345/4885TTR 3973/4885
US-20260091016-A1 Composition for preventing and/or combating neuroinflammation, particularly in neuropsychiatric and neurological diseases CNTN1, GAP43, BDNF AKR1B10 2936/4885AKR1B1 2847/4885TTR 1796/4885
US-20150038466-A1 PAIN RELIEF COMPOUNDS OPRL1, OPRK1, TRPV1 AKR1B10 1601/4885AKR1B1 1390/4885TTR 1663/4885
US-20150274633-A2 PAIN RELIEF COMPOUNDS OPRL1, OPRK1, TRPV1 AKR1B10 1601/4885AKR1B1 1390/4885TTR 1663/4885
US-20260137644-A1 COMPOSITIONS INCLUDING CAFFEIC ACID PHENETHYL ESTER TFEB, CUTA, PPARG AKR1B10 2412/4885AKR1B1 2733/4885TTR 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.